Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218029 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
A Phase 3 study of Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 815
- Enrollment target
- 20
- Study locations
NCT07218029 is a Phase 3 study of Pulmonary Arterial Hypertension that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 815 participants, above the 449-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (82% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT07218029, a Phase 3 study of Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 815 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can treat symptoms of PAH but do not stop PAH from getting worse. Sotatercept is a study medicine designed to treat PAH. It is a targeted therapy, which is a treatment that works on certain proteins that play a role in causing PAH. This is a long-term follow-up (LTFU) study. People who took part in certain other studies testing sotatercept for PAH may be able to join this study. The goal of this study is to learn about the long-term safety of sotatercept and if people tolerate it when taken with standard PAH treatment over a longer period of time.
Conditions Studied
Interventions
- BIOLOGICAL Sotatercept
Study Locations (20)
California
- University of California San Diego Health ( Site 1002) - La Jolla
- UCSF Helen Diller Medical Center at Parnassus Heights ( Site 1019) - San Francisco
- Jeffrey S. Sager, MD Medical Corporation ( Site 1060) - Santa Barbara
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 1028) - Torrance
Ohio
- The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001) - Cincinnati
- University of Cincinnati Medical Center ( Site 1035) - Cincinnati
- Ohio State University Wexner Medical Center ( Site 1032) - Columbus
Arizona
- Pulmonary Associates, PA ( Site 1008) - Phoenix
Colorado
- University of Colorado Hospital ( Site 1013) - Aurora
Florida
- Mayo Clinic Jacksonville ( Site 1045) - Jacksonville
Kansas
- University of Kansas Medical Center ( Site 1020) - Kansas City
Kentucky
- Norton Pulmonary Specialists ( Site 1066) - Louisville
Massachusetts
- Tufts Medical Center ( Site 1012) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 815 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2028-12-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218029
The ClinicalTrials.gov registry entry for NCT07218029 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 815 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 449-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (82% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Sotatercept is the first listed.
NCT07218029 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT07218029 about?
NCT07218029 is a clinical study titled "A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)". Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) trea...
What is the current status of trial NCT07218029?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 815 participants. The study started on 2021-05-12. Estimated completion is 2028-12-07.
What conditions does trial NCT07218029 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT07218029?
The interventions under investigation include: Sotatercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT07218029?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218029 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
ACTIVE NOT RECRUITING · Phase 3
-
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 3
-
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
COMPLETED · Phase 3
-
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.